Francesca Timoneri

Dr. Francesca Timoneri

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Cancer Letters
Verified
Journal Article
Open access
AGAlessia Gallo
Alessia Gallo
SVSerena Vella
Serena Vella
MMMonica Miele
Monica Miele
FTFrancesca Timoneri
Francesca Timoneri
MBMariangela Di Bella
Mariangela Di Bella
PCPier Giulio Conaldi
Pier Giulio Conaldi
The human EBV-transformed lymphoblastoid cell line (LCL), obtained by infecting peripheral blood monocular cells with Epstein-Barr Virus, has been extensively used for human genetic, pharmacogenomic, and immunologic studies. Recently, the role of exosomes has also been indicated as crucial in the crosstalk between EBV and the host microenvironment. Because the role that the LCL and LCL exosomal cargo might play in maintaining persistent infection, and since little is known regarding the non-coding RNAs of LCL, the aim of our work was the comprehensive characterization of this class of RNA, cellular and viral miRNAs, and cellular lncRNAs, in LCL compared with PBMC derived from the same donors. In this study, we have demonstrated, for the first time, that all the viral miRNAs expressed by LCL are also packaged in the exosomes, and we found that two miRNAs, ebv-miR-BART3 and ebv-miR-BHRF1-1, are more abundant in the exosomes, suggesting a microvescicular viral microRNA transfer. In addition, lncRNA profiling revealed that LCLs were enriched in lncRNA H19 and H19 antisense, and released these through exosomes, suggesting a leading role in the regulation of the tumor microenvironment.

Verified
Journal Article
Open access
PDF file
CCCinzia Chinnici
Cinzia Chinnici
Gioacchin IannoloGioacchin Iannolo
Gioacchin Iannolo
ECEttore Cittadini
Ettore Cittadini
ACAnna Paola Carreca
Anna Paola Carreca
DNDavid Nascari
David Nascari
PCPier Giulio Conaldi
Pier Giulio Conaldi
Despite low levels of vascular endothelial growth factor (VEGF)-A, the secretome of human Wharton’s jelly (WJ) mesenchymal stromal cells (MSCs) effectively promoted proangiogenic responses in vitro, which were impaired upon the depletion of small (~140 nm) extracellular vesicles (EVs). The isolated EVs shared the low VEGF-A profile of the secretome and expressed five microRNAs, which were upregulated compared to fetal dermal MSC-derived EVs. These upregulated microRNAs exclusively targeted the VEGF-A gene within 54 Gene Ontology (GO) biological processes, 18 of which are associated with angiogenesis. Moreover, 15 microRNAs of WJ-MSC-derived EVs were highly expressed (Ct value ≤ 26) and exclusively targeted the thrombospondin 1 (THBS1) gene within 75 GO biological processes, 30 of which are associated with the regulation of tissue repair. The relationship between predicted microRNA target genes and WJ-MSC-derived EVs was shown by treating human umbilical-vein endothelial cells (HUVECs) with appropriate doses of EVs. The exposure of HUVECs to EVs for 72 h significantly enhanced the release of VEGF-A and THBS1 protein expression compared to untreated control cells. Finally, WJ-MSC-derived EVs stimulated in vitro tube formation along with the migration and proliferation of HUVECs. Our findings can contribute to a better understanding of the molecular mechanisms underlying the proangiogenic responses induced by human umbilical cord-derived MSCs, suggesting a key regulatory role for microRNAs delivered by EVs.

15 November 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
AMalessandra mularoni
alessandra mularoni
ACandrea cona
andrea cona
MBMatteo Bulati
Matteo Bulati
RBRosalia Busà
Rosalia Busà
MMMonica Miele
Monica Miele
MLMario Luppi
Mario Luppi
Kaposi sarcoma herpesvirus/human herpesvirus-8 (HHV-8) neoplastic and non-neoplastic disease in solid organ transplant (SOT) recipients can be life-threatening. We evaluated the seroprevalence of HHV-8 infection among donors (D) and recipients (R), the incidence of HHV-8 transmission/reactivation, and the clinical characteristics, management, and outcomes of HHV-8-related diseases, including Kaposi sarcoma herpesvirus-associated inflammatory cytokine syndrome (KICS), in consecutive SOT patients from 2011 to 2023. HHV-8 seroprevalence was 3.3% in 1349 donors and 8.4% in 1856 recipients screened (p<0.0001). Among the D+/R- group (n=49), 13 patients developed HHV-8-related diseases: 7 liver recipients had KICS, and 1 lung recipient had Kaposi sarcoma (KS) with subsequent KICS. Four KICS patients treated with rituximab survived, while the 3 patients not treated with rituximab died. Within the D-/R- group, out of 5 (0.3%) patients with non-donor-derived primary HHV-8 infection, 3 liver recipients developed KICS. In the R+ patients (n=155), 3 developed KS. In our cohort, 25/944 (2.6%) liver transplant recipients had a primary HHV-8 infection, and 10 of them (40%) developed KICS; 40% (4/10) of HHV-8 seropositive heart transplant recipients developed reactivation and 2 of them (50%) had fatal KS. Serologic screening and molecular surveillance of D+/R- patient groups facilitate early recognition and effective therapy of KICS.

15 June 2010 in Transplantation
Verified
Journal Article
Closed access
TYToshiyuki Yamamoto
Toshiyuki Yamamoto
AMAtsuyoshi Mita
Atsuyoshi Mita
Camillo  RicordiCamillo Ricordi
Camillo Ricordi
SMShari Messinger
Shari Messinger
AMAtsushi Miki
Atsushi Miki
HIHirohito Ichii
Hirohito Ichii
Objectives. Recent studies demonstrated that prolactin (PRL) has beneficial effects on β cells for islet transplantation. We examined the effect of human recombinant PRL (rhPRL) supplementation to the culture media to determine its potential use in the context of clinical islet transplantation. Materials and Methods. Each human islet isolated from 14 deceased multiorgan donors was cultured in Miami modified media-1 supplemented with or without rhPRL (500 μg/L) for 48 hr. β-Cell survival and proliferation (BrdU and Ki-67) were determined by laser scanning cytometry. The cytoprotective effects of rhPRL against noxious stimuli were assessed by flow cytometry (tetramethylrhodamine ethyl ester). Cytokine/chemokine and tissue factor productions were measured in vitro, and islet potency was assessed in vivo in diabetic immunodeficient mice. Results. β-Cell survival during culture was 37% higher in the rhPRL group than in control (P=0.029). rhPRL protected β cells in vitro from cytokines, Nitric oxide donor, and H2O2. The exposure to rhPRL did not affect human β-cell proliferation with our protocol. rhPRL treatment did not alter cytokine/chemokine and tissue factor production in vitro or affected human islet functionality in vivo: recipient mice achieved normoglycemia with a comparable tempo, whereas loss of graft function was observed in two of the seven mice in the control group and in none of the rhPRL group (p=n.s.). Conclusion. rhPRL supplementation to islet culture media improved human β-cell-specific survival without altering islet quality. Addition of rhPRL to cultured islets may grant a more viable β-cell mass in culture. The development of β-cell cytoprotective strategies will be of assistance in improving islet transplantation outcomes.

26 July 2008 in Diabetologia
Verified
Journal Article
Closed access
PDF file
DKD. Klein
D. Klein
FTFrancesca Timoneri
Francesca Timoneri
HIHirohito Ichii
Hirohito Ichii
Camillo  RicordiCamillo Ricordi
Camillo Ricordi
RPR. L. Pastori
R. L. Pastori

1 June 2015 in Cell Transplantation
Verified
Journal Article
Open access
CCCinzia Chinnici
Cinzia Chinnici
FTFrancesca Timoneri
Francesca Timoneri
Giandomenico AmicoGiandomenico Amico
Giandomenico Amico
GPGiada Pietrosi
Giada Pietrosi
GVGiovanni Vizzini
Giovanni Vizzini
PCPier Giulio Conaldi
Pier Giulio Conaldi
This study was designed to assess liver-specific functions of human fetal liver cells proposed as a potential source for hepatocyte transplantation. Fetal liver cells were isolated from livers of different gestational ages (16-22 weeks), and the functions of cell preparations were evaluated by establishing primary cultures. We observed that 20- to 22-week-gestation fetal liver cell cultures contained a predominance of cells with hepatocytic traits that did not divide in vitro but were functionally competent. Fetal hepatocytes performed liver-specific functions at levels comparable to those of their adult counterpart. Moreover, exposure to dexamethasone in combination with oncostatin M promptly induced further maturation of the cells through the acquisition of additional functions (i.e., ability to store glycogen and uptake of indocyanine green). In some cases, particularly in cultures obtained from fetuses of earlier gestational ages (16-18 weeks gestation), cells with mature hepatocytic traits proved to be sporadic, and the primary cultures were mainly populated by clusters of proliferating cells. Consequently, the values of liver-specific functions detected in these cultures were low. We observed that a low cell density culture system rapidly prompted loss of the mature hepatocytic phenotype with downregulations of all the liver-specific functions. We found that human fetal liver cells can be cryopreserved without significant loss of viability and function and evaluated up to 1 year in storage in liquid nitrogen. They might, therefore, be suitable for cell banking and allow for the transplantation of large numbers of cells, thus improving clinical outcomes. Overall, our results indicate that fetal hepatocytes could be used as a cell source for hepatocyte transplantation. Fetal liver cells have been used so far to treat end-stage liver disease. Additional studies are needed to include these cells in cell-based therapies aimed to treat liver failure and inborn errors of metabolism.